Menu
A promising therapeutic target for treating nerugeneratic disorders
The protein GSK-3 is a causative factor behind a broad spectrum of neurodegenerative disorders including Alzheimer’s and Parkinson’s disease, mood behavior disorders, and certain orphan indications such as Fragile X syndrome and Huntington’s disease. Inhibition of GSK-3 should limit the diseases severity, its progression, and to rescue pathological symptoms. The challenge is to find drugs that inhibit GSK-3 effectively and safely e.g. with limited side effects. To address this challenge, we designed and produced unique GSK-3 inhibitors that fulfill these standards and show effective therapeutic activity in several in vivo diseases models
The protein GSK-3 is a causative factor behind a broad spectrum of neurodegenerative disorders including Alzheimer’s and Parkinson’s disease, mood behavior disorders, and certain orphan indications such as Fragile X syndrome and Huntington’s disease. Inhibition of GSK-3 should limit the diseases severity, its progression, and to rescue pathological symptoms. The challenge is to find drugs that inhibit GSK-3 effectively and safely e.g. with limited side effects. To address this challenge, we designed and produced unique GSK-3 inhibitors that fulfill these standards and show effective therapeutic activity in several in vivo diseases models
Many GSK-3 inhibitors were developed so far, but most of them failed in the preclinical or clinical phase. The problem is an inherent drawback of such inhibitors that act as ‘ATP competitive inhibitors’. Our compounds are designed to inhibit GSK-3 in a different manner which insures high selectivity and safety.
The protein GSK-3 is a causative factor behind a broad spectrum of neurodegen- erative disorders including Alzheimer’s and Parkinson’s disease, mood behavior disorders, and certain orphan indications such as Fragile X syndrome and Huntington’s disease. Inhibition of GSK-3 should limit the diseases severity, its progression, and to rescue pathological symptoms. The challenge is to find drugs that inhibit GSK-3 effectively and safely e.g. with limited side effects. To address this challenge, we designed and produced unique GSK-3 inhibitors that fulfill these standards and show effective therapeutic activity in several in vivo diseases models